Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide for Geographic Atrophy in Dry AMD
NCT00429936Phase 2Completed
- Sponsor
- Sirion Therapeutics, Inc.
- Start
- Dec 2006
- Primary completion
- May 2010
01
Overview
Phase 2, randomised, double-blind trial of fenretinide in geographic atrophy (GA) and age-related macular degeneration (AMD), sponsored by Sirion Therapeutics, Inc. Primary endpoint: Geographic Atrophy lesion progression at 1 year. Started Dec 2006; status: completed.
02
Drugs
fenretinide
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00429936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429936.